GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Institutional Ownership

IGM Biosciences (STU:1K0) Institutional Ownership : 7.57% (As of Apr. 12, 2025)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, IGM Biosciences's institutional ownership is 7.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, IGM Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, IGM Biosciences's Float Percentage Of Total Shares Outstanding is 25.97%.


IGM Biosciences Institutional Ownership Historical Data

The historical data trend for IGM Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Institutional Ownership Chart

IGM Biosciences Historical Data

The historical data trend for IGM Biosciences can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 14.06 14.35 14.14 14.28 14.59 13.91 13.34 7.59 7.57 7.57

IGM Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


IGM Biosciences Business Description

Traded in Other Exchanges
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Headlines

No Headlines